Rising Meningococcal Infections Prompt Public Health Response in France
Health authorities intensify vaccination efforts in light of unprecedented increase in meningococcal infections among young populations.
France is experiencing a significant surge in invasive meningococcal infections (IMI), prompting health authorities to raise public health alerts and enhance vaccination initiatives aimed at younger age groups.
Each year, approximately 500 cases of IMI, caused by the bacterium _Neisseria meningitidis_, are reported nationwide.
This serious illness can lead to meningitis, an inflammation of the membranes surrounding the brain and spinal cord, or septicemia, a severe blood infection.
With a mortality rate of 1 in 10 patients and long-term sequelae affecting a quarter of those infected, health professionals are increasingly alarmed by the upward trend in cases.
Following a notable decrease in infections during the COVID-19 pandemic—largely attributed to barrier measures—the number of reported IMI began to rise in 2022. In 2024, France recorded 616 cases, a 10% increase compared to the previous year, marking the highest annual figure since 2010. The trend has continued into 2025, with early indicators showing a new peak in cases.
Dr. Hervé Haas, a pediatric infectious disease specialist at the CHU of Nice, has highlighted multiple factors contributing to this rise.
The resumption of social interactions has allowed for greater transmission of the meningococcal bacteria.
Of particular importance is the exceptional influenza outbreak that affected France during the winter of 2024. The simultaneous circulation of three influenza viruses—two strains of virus A and virus B—has compromised respiratory mucosa among the population, increasing susceptibility to meningococcal infections.
Furthermore, vaccination coverage against influenza was notably low, exacerbating the situation.
In France, four main serogroups of meningococcal disease are relevant: B, C, W, and Y. Vaccination campaigns against serogroup C have nearly eradicated this particular strain among infants.
Currently, serogroup B accounts for approximately 50% of cases, while W and Y serogroups—previously uncommon—now account for nearly half of infections, a shift attributed to increased international exchanges.
Certain demographic groups are more vulnerable to these infections.
Infants under one year old, young children, and adolescents aged 15 to 24 are at heightened risk.
Immature immune systems in infants placed them at a disadvantage in combating infections like meningococcus, whereas adolescents and young adults are particularly exposed due to communal living situations such as schools, boarding houses, and social gatherings.
This demographic also plays a crucial role in the transmission of the bacteria, often acting as asymptomatic carriers.
Vaccination serves as the sole effective prevention against these unpredictable and serious infections, leading authorities to strengthen and broaden vaccination strategies since January 2025. While antibiotics are necessary for treatment, they do not always prevent severe outcomes due to rapid inflammatory responses triggered by the bacteria, complicating timely diagnosis; early symptoms often resemble those of less severe conditions such as the flu or gastroenteritis.
The vaccine for serogroup B, the most common form of IMI, is heavily recommended for adolescents and young adults due to their significant role in bacterial transmission.
However, it is not mandatory.
The vaccine does not meet the criteria for a mandatory vaccination program, as it primarily protects the vaccinated individual without preventing the bacteria's spread.
Furthermore, enforcing such a mandate for adolescents is complicated by difficulties in monitoring vaccination schedules compared to younger children.
Cultural hesitance toward mandatory vaccinations in France has also influenced public health strategies, which emphasize informed decision-making among young people and their families.
Regarding older adults, vaccination against meningococcus is not currently reimbursed for individuals over 65 years, but this policy may change if it is confirmed that they are also at risk, as emerging data indicate similar infection rates among older adults and young adults.
Each year, approximately 500 cases of IMI, caused by the bacterium _Neisseria meningitidis_, are reported nationwide.
This serious illness can lead to meningitis, an inflammation of the membranes surrounding the brain and spinal cord, or septicemia, a severe blood infection.
With a mortality rate of 1 in 10 patients and long-term sequelae affecting a quarter of those infected, health professionals are increasingly alarmed by the upward trend in cases.
Following a notable decrease in infections during the COVID-19 pandemic—largely attributed to barrier measures—the number of reported IMI began to rise in 2022. In 2024, France recorded 616 cases, a 10% increase compared to the previous year, marking the highest annual figure since 2010. The trend has continued into 2025, with early indicators showing a new peak in cases.
Dr. Hervé Haas, a pediatric infectious disease specialist at the CHU of Nice, has highlighted multiple factors contributing to this rise.
The resumption of social interactions has allowed for greater transmission of the meningococcal bacteria.
Of particular importance is the exceptional influenza outbreak that affected France during the winter of 2024. The simultaneous circulation of three influenza viruses—two strains of virus A and virus B—has compromised respiratory mucosa among the population, increasing susceptibility to meningococcal infections.
Furthermore, vaccination coverage against influenza was notably low, exacerbating the situation.
In France, four main serogroups of meningococcal disease are relevant: B, C, W, and Y. Vaccination campaigns against serogroup C have nearly eradicated this particular strain among infants.
Currently, serogroup B accounts for approximately 50% of cases, while W and Y serogroups—previously uncommon—now account for nearly half of infections, a shift attributed to increased international exchanges.
Certain demographic groups are more vulnerable to these infections.
Infants under one year old, young children, and adolescents aged 15 to 24 are at heightened risk.
Immature immune systems in infants placed them at a disadvantage in combating infections like meningococcus, whereas adolescents and young adults are particularly exposed due to communal living situations such as schools, boarding houses, and social gatherings.
This demographic also plays a crucial role in the transmission of the bacteria, often acting as asymptomatic carriers.
Vaccination serves as the sole effective prevention against these unpredictable and serious infections, leading authorities to strengthen and broaden vaccination strategies since January 2025. While antibiotics are necessary for treatment, they do not always prevent severe outcomes due to rapid inflammatory responses triggered by the bacteria, complicating timely diagnosis; early symptoms often resemble those of less severe conditions such as the flu or gastroenteritis.
The vaccine for serogroup B, the most common form of IMI, is heavily recommended for adolescents and young adults due to their significant role in bacterial transmission.
However, it is not mandatory.
The vaccine does not meet the criteria for a mandatory vaccination program, as it primarily protects the vaccinated individual without preventing the bacteria's spread.
Furthermore, enforcing such a mandate for adolescents is complicated by difficulties in monitoring vaccination schedules compared to younger children.
Cultural hesitance toward mandatory vaccinations in France has also influenced public health strategies, which emphasize informed decision-making among young people and their families.
Regarding older adults, vaccination against meningococcus is not currently reimbursed for individuals over 65 years, but this policy may change if it is confirmed that they are also at risk, as emerging data indicate similar infection rates among older adults and young adults.